USA |NASDAQ |USD
Report Date | Period Ending | EPS Forecast | Last Quarter's EPS | Last Year's EPS |
---|---|---|---|---|
Aug 10, 2022 | Jun 2022 | - | - | $-0.28 |
Report Date | Period Ending | Revenue Forecast | Last Quarter’s Revenue | Last Year’s Revenue |
---|---|---|---|---|
Aug 10, 2022 | Jun 2022 | - | - | $14.58M |
4d Molecular Therapeutics, Inc's next earnings date is Wednesday, Aug 10, 2022 for the fiscal quarter ending Jun 2022.
Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
---|
Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
---|---|---|---|---|
Dec 2022 | 3 | $-3.68 | $-4.32 | $-2.88 |
Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
---|
Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
---|---|---|---|---|
Dec 2022 | 0 / 0 | $-3.68 | $-3.60 | $-2.98 |
Period End | # of Analysts | Revenue Forecast | Low Revenue Forecast | High Revenue Forecast |
---|
Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
---|---|---|---|---|
Dec 2022 | 2 | $1.55M | $0.00 | $3.10M |
Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
---|---|---|---|---|
Mar 23, 2022 | Dec 2021 | $-0.86 | - | - |
Nov 10, 2021 | Sep 2021 | $-0.81 | $-0.82 | -1.86% |
Aug 12, 2021 | Jun 2021 | $-0.68 | $-0.28 | 58.82% |
May 13, 2021 | Mar 2021 | $-1.10 | $-0.61 | 44.55% |
Mar 25, 2021 | Dec 2020 | $-0.66 | $-1.85 | -180.30% |
Dec 31, 2019 | Sep 2019 | - | $-3.12 | - |
Sep 30, 2019 | Jun 2019 | - | $-3.24 | - |
Jun 30, 2019 | Mar 2019 | - | $-1.61 | - |
Mar 31, 2019 | Dec 2018 | - | $-1.61 | - |
Dec 31, 2018 | Sep 2018 | - | $-0.43 | - |
Sep 30, 2018 | Jun 2018 | - | $-0.43 | - |
Jun 30, 2018 | Mar 2018 | - | $-0.52 | - |
Mar 31, 2018 | Dec 2017 | - | $-0.52 | - |
Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
---|---|---|---|---|
Mar 23, 2022 | Dec 2021 | $-2.57 | $-1.71 | - |
Mar 25, 2021 | Dec 2020 | $-3.01 | $-9.82 | - |
Mar 31, 2019 | Dec 2018 | - | $-2.98 | - |
Mar 31, 2018 | Dec 2017 | - | $-0.52 | - |
Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
---|---|---|---|---|
Mar 23, 2022 | Dec 2021 | $170.00K | - | - |
Nov 10, 2021 | Sep 2021 | $170.00K | $1.37M | 8.04% |
Aug 12, 2021 | Jun 2021 | $14.58M | $14.58M | 1.00% |
May 13, 2021 | Mar 2021 | $0.00 | $2.00M | - |
Mar 25, 2021 | Dec 2020 | $0.00 | $-977.00K | - |
Dec 31, 2019 | Sep 2019 | - | - | - |
Sep 30, 2019 | Jun 2019 | - | - | - |
Jun 30, 2019 | Mar 2019 | - | - | - |
Mar 31, 2019 | Dec 2018 | - | - | - |
Dec 31, 2018 | Sep 2018 | - | - | - |
Sep 30, 2018 | Jun 2018 | - | - | - |
Jun 30, 2018 | Mar 2018 | - | - | - |
Mar 31, 2018 | Dec 2017 | - | - | - |
Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
---|---|---|---|---|
Mar 23, 2022 | Dec 2021 | $16.93M | - | - |
Mar 25, 2021 | Dec 2020 | $13.61M | $13.61M | 0.00% |
Mar 31, 2019 | Dec 2018 | - | $14.13M | - |
Mar 31, 2018 | Dec 2017 | - | $5.79M | - |
FDMT's next earnings date is Wednesday, Aug 10, 2022 for the fiscal quarter ending Jun 30, 2022.
4d Molecular Therapeutics, Inc's previous earnings date was May 11, 2022 for its fiscal quarter ended Mar 31, 2022.
4d Molecular Therapeutics, Inc's previous annual earnings date was Mar 25, 2021 for its fiscal year ended Dec 31, 2020.
FDMT's earnings per share (EPS) was $-9.82.
Revenues were $13.61M, better than the forecast of $13.61M by 0.00%, and up by 94.85% from previous year's revenue.
The company reported a net income of $-56.69M.
4d Molecular Therapeutics, Inc reported a free cash flow of $-51.91M for its fiscal year, compared to $-39.91M a year ago.
Get a weekly snapshot of one new investment idea from stock exchanges worldwide.